J Clin Neurol.  2017 Jan;13(1):98-100. 10.3988/jcn.2017.13.1.98.

Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans

• Byun JI
• Sim JY
• Kim M

• KMID: 2364904
• DOI: http://doi.org/10.3988/jcn.2017.13.1.98

Abstract

No abstract available.

MeSH Terms

Migraine Disorders*

Figure

• 

  Fig. 1 Treatment responses after BOTOX therapy. A: Number of patients in each response group and numbers of patients who changed groups at 4 weeks, 3 months, 6 months, and 1 year after the BOTOX treatment. B: Proportions of patients in each response group at 4 weeks, 3 months, 6 months, and 1 year after the BOTOX treatment. BOTOX: OnabotulinumtoxinA.

Reference

1. Levin M. The international classification of headache disorders, 3rd edition (ICHD III)-changes and challenges. Headache. 2013; 53:1383–1395.

2. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30:804–814.

3. Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 2014; 15:54.

4. Barbanti P, Egeo G, Fofi L, Aurilia C, Piroso S. Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine. Neurol Sci. 2015; 36:29–32.

5. asianplasticsurgeryguide.com [internet]. Asian plastic surgery. Comparison of 30 east asian and european facial attributes. Available from: http://www.asianplasticsurgeryguide.com/overview/asianeuropeanface.html.